Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System.

Annals of surgical oncology - 1 May 2026

Dzubnar Jessica M, Habel Laurel A, Jiang Sheng-Fang, Karlea Audrey, Hoodfar Elizabeth, Shim Veronica C

Abstract excerpt

BACKGROUND: Identification of germline pathogenic (PV) and likely pathogenic variants (LPV) can inform patients of their risk for breast cancer, empowering them to utilize risk-reducing strategies. National guidelines for germline testing are the same for invasive breast cancer (IBC) and ductal carcinoma in situ (DCIS); however, data on how testing and results compare for patients with DCIS versus IBC are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Ductal, Breast

Share to Carcinoma, Intraductal, Noninfiltrating

Share to Follow-Up Studies

Share to Genetic Testing

Share to Germ-Line Mutation

Share to Neoplasm Invasiveness

Source

Identifiers

PMID: 41530599
DOI: 10.1245/s10434-025-19053-3

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multigene Germline Testing in Patients with DCIS vs Invasive Breast Cancer in a Large, Integrated Health Care System.PMID 41530599Read ↗

Germline Genetic Testing Among Women ≤ 45 Years of Age with Ductal Carcinoma In Situ Versus Invasive Breast Cancer in a Large Integrated Health Care System.Semantic proximity Read ↗

Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.Semantic proximity Read ↗

Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer.Semantic proximity Read ↗

Germline Multigene Panel Testing in Women With Invasive Lobular Cancer.Semantic proximity Read ↗

Prevalence of BRCA1 and BRCA2 Variants in an Unselected Population of Women With Breast Cancer.Semantic proximity Read ↗

Hereditary cancer testing in a diverse sample across three breast imaging centers.Semantic proximity Read ↗

Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional StudySemantic proximity Read ↗

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer PatientsSemantic proximity Read ↗

Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.Semantic proximity Read ↗

Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.Semantic proximity Read ↗

Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United StatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.